BRIEF

on DIAGNOSTIC MEDICAL (EPA:ALDMS)

DMS Group Sees Revenue Increase and Expands Internationally

Stock price chart of DIAGNOSTIC MEDICAL (EPA:ALDMS) showing fluctuations.

DMS Group has reported a 3% revenue increase in the first half of 2025, reaching €23.6 million, despite a challenging market and unfavorable base effects. This growth is attributed to strong international sales momentum, especially in North America and the Middle East. Revenue from North America surged to €4.1 million, marked by significant contributions from Carestream Health and Fujifilm Healthcare.

The company is expanding its presence internationally, as evidenced by its strategic contract with Ukraine for 120 mobile radiology units, enhancing its role in supporting Ukrainian healthcare infrastructure. Additionally, FDA clearance for its mobile radiology solution! M1 paves the way for immediate commercialization in the U.S., where Medlink Imaging begins first deliveries.

Further, an anticipated strategic partnership with InnoLux points to planned advances in next-generation imaging technology. DMS Group remains confident in achieving its #Imaging2027 strategic goals, focusing on innovation, product diversification, and geographic expansion.

R. P.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all DIAGNOSTIC MEDICAL news